Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $30.00

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its price target raised by Evercore ISI from $25.00 to $30.00 in a research report report published on Wednesday morning, Benzinga reports. Evercore ISI currently has an outperform rating on the stock.

A number of other equities research analysts have also commented on KNSA. Wedbush restated an outperform rating and set a $30.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Tuesday. TheStreet upgraded shares of Kiniksa Pharmaceuticals from a d+ rating to a c rating in a report on Thursday, February 29th.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ:KNSA opened at $17.88 on Wednesday. The firm has a 50 day simple moving average of $19.27 and a 200 day simple moving average of $18.00. Kiniksa Pharmaceuticals has a 52 week low of $10.65 and a 52 week high of $22.09. The company has a market cap of $1.26 billion, a PE ratio of 162.56, a price-to-earnings-growth ratio of 5.59 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Tuesday, April 23rd. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.11). The business had revenue of $79.90 million during the quarter, compared to analysts’ expectations of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.32%. Kiniksa Pharmaceuticals’s revenue for the quarter was up 65.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.18) EPS. On average, equities analysts predict that Kiniksa Pharmaceuticals will post -0.04 earnings per share for the current year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 5,126 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total value of $111,695.54. Following the transaction, the chief accounting officer now owns 17,588 shares in the company, valued at $383,242.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 5,126 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total value of $111,695.54. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares in the company, valued at $383,242.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Michael R. Megna sold 9,659 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $21.45, for a total transaction of $207,185.55. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at $377,262.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,109 shares of company stock worth $709,929. Corporate insiders own 54.23% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. IFP Advisors Inc bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth about $65,000. China Universal Asset Management Co. Ltd. boosted its position in Kiniksa Pharmaceuticals by 349.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock worth $72,000 after purchasing an additional 3,186 shares during the period. Victory Capital Management Inc. bought a new stake in Kiniksa Pharmaceuticals during the third quarter worth approximately $176,000. Dynamic Technology Lab Private Ltd acquired a new position in Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $213,000. Finally, QRG Capital Management Inc. bought a new position in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $249,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.